title: Angiotensin-converting enzyme inhibition reverses luteal phase steroid production in oocyte donors.
abstract: OBJECTIVE
  To determine whether angiotensin-converting enzyme (ACE) inhibition would affect ovarian steroid synthesis in the oocyte donors undergoing controlled ovarian hyperstimulation (COH).
  
  
  METHODS
  The IVF program of the University of Southern California.
  
  
  METHODS
  Prospective matched clinical trial.
  
  
  METHODS
  Twelve oocyte donors were studied in 28 hyperstimulation cycles.
  
  
  METHODS
  Donors underwent a standard COH protocol. Follicle aspiration was performed 34 hours after administration of hCG. After the procedure, seven donors were administered the ACE inhibitor, captopril, 6.25 mg orally twice daily for 4 days. The remaining patients served as controls.
  
  
  METHODS
  Serum E2, P, plasma prorenin, active renin, and angiotensin II (Ang II).
  
  
  RESULTS
  Angiotensin II increased after aspiration in both groups but was significantly lower in those receiving captopril. Peak P in the captopril group was significantly lower than controls (81.8 +/- 27.8 versus 208.5 +/- 23.9 ng/mL [conversion factor to SI unit, 3.180]). Peak E2 was significantly higher (2,222.4 +/- 875.3 versus 425.6 +/- 490.4 pg/mL [conversion factor to SI unit, 3.671]). Active renin and Ang II correlated with P.
  
  
  CONCLUSIONS
  In stimulated cycles, inhibition of Ang II production appears to raise serum E2 and lower P levels. Angiotensin II, therefore, may have a role in the regulation of ovarian steroid synthesis.
authors.affiliation: Division of Reproductive Endocrinology, University of Southern California, Los Angeles.
authors.forename: R S
authors.initials: RS
authors.lastname: Morris
authors.forename: R J
authors.initials: RJ
authors.lastname: Paulson
authors.forename: S R
authors.initials: SR
authors.lastname: Lindheim
authors.forename: R S
authors.initials: RS
authors.lastname: Legro
authors.forename: R A
authors.initials: RA
authors.lastname: Lobo
authors.forename: M V
authors.initials: MV
authors.lastname: Sauer
mesh_terms: D000293:Adolescent; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D002216:Captopril / Q000494:pharmacology*; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology*; D006728:Hormones / Q000096:biosynthesis* / Q000097:blood; D006801:Humans; D008183:Luteal Phase / Q000378:metabolism*; D018587:Oocyte Donation; D010053:Ovary / Q000378:metabolism; D011446:Prospective Studies
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D006063:Chorionic Gonadotropin; D006727:Hormone Antagonists; D006728:Hormones; D002216:Captopril